BrainsWay Ltd. announced that it will be clinically evaluating an innovative stimulation technology in two new feasibility trials. The studies both involve BrainsWay's exclusive, patented "Rotational Field" TMS (or "Deep TMS 360deg??), which employs a method of stimulation that enables activation of a greater number of neurons in the brain. In all currently available forms of TMS, those neurons which are aligned parallel to the coil's electric field are much more likely to be stimulated than other neurons.

Thus, only a fraction of the neurons in the targeted brain region are actually impacted. With the new Rotational Field system now being evaluated, two orthogonal TMS coils are placed perpendicular to each other and are operated with a time lag in order to induce a circularly rotating electric field. This results in uniform stimulation of neurons oriented along a wide variety of directions in the targeted brain region - all within less than a millisecond.

The Company now aims to assess the potential clinical impact of this technology on patients in two newly launched feasibility studies. One study will test the safety and efficacy of this technology in the field of rehabilitation following stroke, a devastating neurological condition. Another study will test the technology in the field of obsessive-compulsive disorder (OCD) utilizing an accelerated protocol.

BrainsWay's existing Deep Transcranial Magnetic Stimulation (Deep TMStm) system is already FDA-cleared to treat OCD using the standard daily protocol via its H7 Coil, and this new study will test the ability to further improve outcomes using Rotational Field stimulation while also reducing the length of the standard treatment. BrainsWay's Rotational Field technology is not commercially available and has not yet been cleared for safety and/or efficacy by the FDA.